Ignite Creation Date:
2024-05-06 @ 10:18 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03213652
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2017-07-10
Brief Title:
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With ALK or ROS1 Genomic Alterations A Pediatric MATCH Treatment Trial
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Wilms Tumor |
| Advanced Malignant Solid Neoplasm |
| Malignant Solid Neoplasm |
| Recurrent Ependymoma |
| Recurrent Ewing SarcomaPeripheral Primitive Neuroectodermal Tumor |
| Recurrent Hepatoblastoma |
| Recurrent Langerhans Cell Histiocytosis |
| Recurrent Malignant Germ Cell Tumor |
| Recurrent Malignant Glioma |
| Recurrent Malignant Solid Neoplasm |
| Recurrent Medulloblastoma |
| Recurrent Neuroblastoma |
| Recurrent Non-Hodgkin Lymphoma |
| Recurrent Osteosarcoma |
| Recurrent Primary Central Nervous System Neoplasm |
| Recurrent Rhabdoid Tumor |
| Recurrent Rhabdomyosarcoma |
| Recurrent Soft Tissue Sarcoma |
| Refractory Ependymoma |
| Refractory Ewing SarcomaPeripheral Primitive Neuroectodermal Tumor |
| Refractory Hepatoblastoma |
| Refractory Langerhans Cell Histiocytosis |
| Refractory Malignant Germ Cell Tumor |
| Refractory Malignant Glioma |
| Refractory Malignant Solid Neoplasm |
| Refractory Medulloblastoma |
| Refractory Neuroblastoma |
| Refractory Non-Hodgkin Lymphoma |
| Refractory Osteosarcoma |
| Refractory Primary Central Nervous System Neoplasm |
| Refractory Rhabdoid Tumor |
| Refractory Rhabdomyosarcoma |
| Refractory Soft Tissue Sarcoma |
Keywords: